Preventing nausea after stem cell transplant: olanzapine vs dexamethasone
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial compares two anti-nausea drug regimens (one with olanzapine, one with dexamethasone) to prevent delayed nausea and vomiting after a stem cell transplant for multiple myeloma. It aims to find which is better at controlling these side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are diagnosed with multiple myeloma
- You are scheduled for an autologous stem cell transplant (using your own cells)
- You will receive the chemotherapy drug melphalan as part of your transplant preparation
- You are between 18 and 65 years old
- You are in generally good health (able to care for yourself, up and about more than half the day)
- You have not had nausea or vomiting in the 2 days before the study starts
- You have not taken certain anti-nausea medications recently
- Your kidney function is adequate (creatinine clearance above 60 mL/min)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a lower dose of olanzapine (2.5 mg) works as well as the usual dose (5 mg) for preventing nausea and vomiting caused by high-dose melphalan chemotherapy. It is for people receiving their own stem cell transplant.
This trial tests whether adding dexamethasone to an antibody-based combination therapy works better for multiple myeloma that has come back after previous treatments. If you have had 1 to 3 prior therapies and are eligible for one of two standard drug regimens, this study may help find the best approach for you.
This study tests if two medicines given together, fosaprepitant and palonosetron, can prevent nausea and vomiting caused by strong chemotherapy given over several days. It's for people who have never had chemo before and are about to start a multi-day treatment for a solid tumor.
This trial tests if adding olanzapine to standard anti-nausea medicines can better prevent vomiting in children and teens who still vomit despite current treatment. It aims to help those aged 5 to 18 receiving strong chemotherapy.
This study tests two medications (fosrolapitant and palonosetron) to prevent severe nausea and vomiting in patients with esophageal or lung cancer who are receiving chemotherapy combined with immunotherapy. If the medications work well, they could help patients feel better during treatment and complete their cancer care more comfortably.
This trial tests a new anti-nausea medicine combination for breast cancer patients getting AC chemotherapy, specifically designed for those with diabetes, obesity, or other metabolic issues. It aims to reduce the need for steroids, which can be riskier for these patients.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.